Global biotechnology leader builds on Xcellerex heritage to now offer X-platform bioreactors. X-platform bioreactors can be used for monoclonal antibodi...
As disclosed in September 2022, Avenue received meeting minutes from the FDA regarding a Type A meeting conducted on August 9, 2022, for IV Tramadol. At th...
In April 2022, Telix secured the exclusive worldwide rights to develop and commercialise radiolabelled forms of olaratumab for the diagnosis and treatment ...
The increased presence in the U.S. comes as Atmo Biosciences prepares to begin a multi-site pivotal study to support a U.S. Food and Drug Administration (F...
PRA023 is a novel, late-stage candidate for ulcerative colitis and Crohn’s disease and other autoimmune conditions Prometheus Biosciences&rs...
"Completion of enrollment in the first cohort of the Phase 1b MAD study is an important milestone in the development of this novel treatment for ADPKD," sa...
Pfizer Inc. (NYSE:PFE) announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Supplemental New Drug Applications (sNDAs) fo...
Relapsed or refractory precursor B-cell acute lymphoblastic leukemia Bleeding due to hemophilia A Non-small cell lung cancer Unresectable or metastati...
Conventional high-content screening experiments typically focus on extracting imaging data relating to predefined, specific features to identify drugs or d...
The rising prevalence of chronic diseases coupled with increasing research activities for cell-based research is found to be the major factor driving the...
Accord BioPharma, the U.S. specialty division of Intas Pharmaceuticals, Ltd., focused on development of oncology, immunology, and critical care therapies, ...
-EU and UK filings completed in 2022; submissions validated by EMA and MHRA and the review procedure has begun as of January 2023- -Vertex Pharmac...
Therapeutic Solutions International (TSOI) Spin Off Company Campbell Neurosciences announced new data, covered by its previously filed patents, demonstrati...
MAILISHU is the world's second approved Biosimilars of Denosumab for the osteoporosis in postmenopausal women at high risk of fracture. The drug can signif...
© 2025 Biopharma Boardroom. All Rights Reserved.
